MEDICOMP INC. PARTNERS ON THE FRONT LINES WITH LENOX HILL HOSPITAL & NORTHWELL HEALTH SYSTEM TO MONITOR COVID-19 PATIENTS
MELBOURNE, Fl., April 2, 2020 – Medicomp, Inc., a technology leader in remote and wireless cardiac monitoring, is pleased to announce a strategic partnership with New York based Lenox Hill Hospital, part of the Northwell Health system. Located in the epicenter of the US coronavirus pandemic, Lenox Hill Hospital will be using Medicomp’s TelePatch™ mobile cardiac telemetry (MCT) monitor to measure the heart’s electrical conduction for abnormalities in patients that have been prescribed certain medications in the treatment of COVID-19. Specifically, the drug therapies of chloroquine, hydroxychloroquine and azithromycin all prolong QT interval, raising concerns about the risk of arrhythmic death from individual or concurrent use of these medications.* Drug-induced QT prolongation has long served as a surrogate indicator for increased risk of drug-associated torsades de pointes (TdP), a potentially lethal polymorphic ventricular tachycardia.* TelePatch™ will be utilized by Lenox Hill Hospital doctors to monitor patients for QT prolongation, as well as any other arrhythmias that may occur due to COVID-19 drug therapies. This will allow the doctors to better manage the titration of the medications as well as the overall treatment of their patients.
“The Coronavirus Pandemic presented Lenox Hill Hospital with an unprecedented challenge to monitor patients who were starting treatments for COVID-19 that could adversely affect their rhythm status. We were experiencing a demand that exceeded our current cardiac telemetry unit resources.” said Dr. Nicholas Skipitaris, Director of Cardiac Electrophysiology at Lenox Hill Heart and Lung – Northwell Health. “We partnered with Medicomp to utilize their unique TelePatch™ Mobile Cardiac Telemetry technology to infinitely expand our capacity to monitor patients placed on these treatments for COVID-19 within Lenox Hill Hospital.”
Medicomp has developed the most advanced ambulatory cardiac monitors on the market today including the only line of monitors offering algorithmic analysis of beat-for-beat Rate, Rhythm, Morphology, and P-Wave analysis. To learn more about how we can help organizations during these uncertain and ever-changing times, please contact Randall Martinek, Executive Vice President of Commercialization, at 877-930-1598 or via email at email@example.com.
About Medicomp Inc.
Founded in 1981, Medicomp is one of the oldest and most respected providers of ambulatory cardiac monitoring products and services in the United States. The company is recognized as a technology leader in the telemedicine industry – pioneering leading-edge products and services and developing new applications that result in better clinical outcomes across multiple specialties. Medicomp is headquartered in Melbourne, Florida, with multiple clinical monitoring centers nationwide, providing remote monitoring to patients throughout the world. For more information, visit www.medicompinc.com.
* Timothy F. Simpson, MD, PharmD; Richard J. Kovacs, MD, FACC; and Eric C. Stecker, MD, MPH, FACC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. Cardiology Magazine. March 29, 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19